NCT04667910ranibizumab601macular oedemaBRVOCRVONCT04667897
…ouble-masked, active-controlled phase IIa trials ( NCT04667897, NCT04667910) conducted at 12 Chinese sites (2021–2022), 120 patients were a…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04667910 ×
NCT04667910
This funder is selected. Its supporting articles are shown below.